- Home
- XYL vs IQV Comparison
XYL vs IQV Comparison
Compare XYL & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XYL
- IQV
- Stock Information
- Founded
- XYL 2011
- IQV 1982
- Country
- XYL United States
- IQV United States
- Employees
- XYL N/A
- IQV N/A
- Industry
- XYL Fluid Controls
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- XYL Industrials
- IQV Health Care
- Exchange
- XYL Nasdaq
- IQV Nasdaq
- Market Cap
- XYL 28.8B
- IQV 31.6B
- IPO Year
- XYL N/A
- IQV 2013
- Fundamental
- Price
- XYL $113.13
- IQV $168.02
- Analyst Decision
- XYL Buy
- IQV Strong Buy
- Analyst Count
- XYL 10
- IQV 18
- Target Price
- XYL $149.89
- IQV $248.72
- AVG Volume (30 Days)
- XYL 1.6M
- IQV 1.5M
- Earning Date
- XYL 04-29-2025
- IQV 05-01-2025
- Dividend Yield
- XYL 1.35%
- IQV N/A
- EPS Growth
- XYL 30.82
- IQV 2.74
- EPS
- XYL 3.65
- IQV 7.49
- Revenue
- XYL $8,562,000,000.00
- IQV $15,405,000,000.00
- Revenue This Year
- XYL $2.98
- IQV $4.25
- Revenue Next Year
- XYL $5.29
- IQV $6.17
- P/E Ratio
- XYL $32.52
- IQV $23.21
- Revenue Growth
- XYL 16.27
- IQV 2.81
- 52 Week Low
- XYL $113.26
- IQV $169.11
- 52 Week High
- XYL $146.08
- IQV $252.88
- Technical
- Relative Strength Index (RSI)
- XYL 28.41
- IQV 30.96
- Support Level
- XYL $116.52
- IQV $169.37
- Resistance Level
- XYL $120.30
- IQV $188.39
- Average True Range (ATR)
- XYL 2.39
- IQV 4.92
- MACD
- XYL -0.59
- IQV -0.99
- Stochastic Oscillator
- XYL 4.65
- IQV 3.29
Stock Price Comparison Chart: XYL vs IQV
About XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.